Trial
NCT01751425
Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
M.D. Anderson Cancer Center
Collaborators
National Cancer Institute (NCI)
Condition
Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Intervention
Dasatinib
Why stopped
Per PI Request. 2) No additional benefit was noted with the addition of Ruxolitinib.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-06-03